Literature DB >> 21037871

American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

M Elizabeth H Hammond1, Daniel F Hayes, Antonio C Wolff, Pamela B Mangu, Sarah Temin.   

Abstract

ASCO and CAP collaborated to produce an evidence-based guideline on estrogen and progesterone receptor testing in breast cancer to produce optimal testing performance.

Entities:  

Year:  2010        PMID： 21037871      PMCID： PMC2900870          DOI： 10.1200/JOP.777003

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  3 in total

Review 1.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  Arch Pathol Lab Med       Date:  2010-07       Impact factor: 5.534

2.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

Review 3.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544
  3 in total
  225 in total

1.  Commentary: improving breast cancer testing for patients-the secret sauce is collaboration.

Authors:  M Elizabeth H Hammond
Journal:  J Oncol Pract       Date:  2010-07       Impact factor: 3.840

2.  Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis.

Authors:  Y X Yin; F Shen; H Pei; Y Ding; Hua Zhao; Min Zhao; Q Chen
Journal:  Tumour Biol       Date:  2012-05-30

3.  Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer.

Authors:  Min Ying; Yingjian He; Meng Qi; Bin Dong; Aiping Lu; Jinfeng Li; Yuntao Xie; Tianfeng Wang; Benyao Lin; Tao Ouyang
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

4.  Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis.

Authors:  N Wu; F Fu; L Chen; Y Lin; P Yang; C Wang
Journal:  Clin Transl Oncol       Date:  2019-06-20       Impact factor: 3.405

Review 5.  Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.

Authors:  Priyanka Sharma
Journal:  Curr Treat Options Oncol       Date:  2018-04-14

6.  Expression of FOXM1 and related proteins in breast cancer molecular subtypes.

Authors:  Jeong-Ju Lee; Hee Jin Lee; Byung-Ho Son; Sung-Bae Kim; Jin-Hee Ahn; Seung Do Ahn; Eun Yoon Cho; Gyungyub Gong
Journal:  Int J Exp Pathol       Date:  2016-06-09       Impact factor: 1.925

7.  Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.

Authors:  Albert J Farias; Xianglin L Du
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-05-17       Impact factor: 4.254

8.  CKS1BP7, a Pseudogene of CKS1B, is Co-Amplified with IGF1R in Breast Cancers.

Authors:  Yansong Liu; Wei Wang; Yan Li; Feifei Sun; Jiaxiang Lin; Li Li
Journal:  Pathol Oncol Res       Date:  2017-04-24       Impact factor: 3.201

9.  Downregulation of the transcription factor, FoxD3, is associated with lymph node metastases in invasive ductal carcinomas of the breast.

Authors:  Hua Zhao; Daozhen Chen; Jiayuan Wang; Yongxiang Yin; Qiong Gao; Ye Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

10.  Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer.

Authors:  Willemijne A M E Schrijver; Petra van der Groep; Laurien Dc Hoefnagel; Natalie D Ter Hoeve; Ton Peeters; Cathy B Moelans; Paul J van Diest
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.